H2 Blockers for Acid Reflux

H2 blockers occupy a practical middle ground in acid management — more effective and longer-acting than antacids, but less potent and with fewer long-term concerns than proton pump inhibitors. Originally developed in the 1970s as the first class of drugs capable of meaningfully suppressing gastric acid production, H2 blockers transformed the treatment of peptic ulcer disease before PPIs arrived to largely replace them in that role. Today, their primary value lies in situations where on-demand, preventive acid control is needed for predictable symptoms, or where a lower-intensity alternative to daily PPIs is clinically appropriate.

This article covers how H2 blockers work, what distinguishes the available agents, when they are the right choice over antacids or PPIs, and their safety profile in adults. For the broader context of acid management medications, the overview of digestive medications maps all classes together. For information on the more potent option, the article on proton pump inhibitors covers their mechanisms, appropriate uses, and long-term safety concerns in detail. For a comparison with the less potent option, the guide on antacids for adults explains how neutralisation differs from suppression.

How H2 Blockers Work

H2 blockers — formally called H2 receptor antagonists — work by competitively blocking histamine H2 receptors on the acid-secreting parietal cells in the stomach lining. Histamine is one of three major stimuli for gastric acid secretion: when food enters the stomach, histamine is released from nearby enterochromaffin-like cells and binds to H2 receptors on parietal cells, triggering acid production via the cyclic AMP signalling pathway. By occupying these receptors without activating them, H2 blockers block this stimulatory signal.

This mechanism is selective: H2 blockers do not block the other two acid-stimulating pathways — gastrin and acetylcholine. This is why H2 blockers suppress but do not eliminate acid production, typically achieving around 50% reduction in meal-stimulated acid secretion at standard doses. The acid suppression begins within 30 to 60 minutes of dosing, reaches its peak at 1 to 3 hours, and provides meaningful coverage for 6 to 12 hours — substantially longer than any antacid, but shorter and less complete than the 24-hour near-total suppression from PPIs.

Unlike PPIs, H2 blockers are not prodrugs — they do not require activation and work regardless of whether food has been consumed. This gives them a practical advantage for on-demand or pre-meal use: you can take an H2 blocker 30 minutes before a restaurant meal or before lying down after dinner and reliably achieve acid suppression during the predictable window of risk.

The Available H2 Blockers: Famotidine, Cimetidine, and Ranitidine

Three H2 blockers have been widely available in most countries: ranitidine (Zantac), famotidine (Pepcid), and cimetidine (Tagamet). Following the global withdrawal of ranitidine in 2019–2020 due to concerns about N-nitrosodimethylamine (NDMA) contamination, famotidine and cimetidine remain the standard OTC H2 blocker options in most markets. A fourth agent, nizatidine (Axid), is available in some regions.

Famotidine is now the preferred H2 blocker for most adults following ranitidine’s withdrawal. It is approximately 8 times more potent than cimetidine on a milligram-per-milligram basis, meaning lower doses achieve equivalent acid suppression. Crucially, famotidine does not inhibit the CYP450 enzyme system — unlike cimetidine — giving it a dramatically simpler drug interaction profile. Standard OTC dosing is 10 to 20 mg once or twice daily; prescription famotidine is used at 20 to 40 mg twice daily for active ulcer treatment. Famotidine is also the H2 blocker preferred alongside clopidogrel in cardiac patients, where the interaction concerns with both omeprazole and cimetidine are avoided.

Cimetidine (Tagamet) was the original H2 blocker and the drug that first demonstrated effective pharmacological acid suppression. It remains available OTC at 200 mg doses. Its main clinical disadvantage is extensive CYP450 enzyme inhibition — it inhibits CYP1A2, CYP2C9, CYP2D6, and CYP3A4 — which produces clinically significant interactions with a long list of drugs including warfarin, theophylline, phenytoin, tricyclic antidepressants, and several antiarrhythmics. For most adults not on complex medication regimens, this is manageable; for older adults on polypharmacy, famotidine is almost always preferable. Cimetidine also has weak anti-androgenic effects at high doses, historically causing gynaecomastia in some male patients — this is not a concern at standard OTC doses.

Ranitidine was the world’s best-selling drug in the 1980s and remained widely used until regulatory agencies including the FDA, EMA, and MHRA withdrew it from all markets in 2020 following the discovery that it degrades to produce NDMA — a probable human carcinogen — both in manufacturing and under storage conditions. Ranitidine products should no longer be in use; any remaining stock should be discarded. The clinical role it previously filled has been replaced by famotidine in essentially all contexts.

Tachyphylaxis: Why H2 Blockers Lose Effectiveness With Daily Use

One of the most clinically important and least widely known properties of H2 blockers is tachyphylaxis — a rapid reduction in drug effectiveness with continuous daily use. Within 2 to 6 weeks of taking an H2 blocker every day, the acid-suppressing effect at a given dose diminishes significantly. The mechanism involves upregulation of H2 receptors on parietal cells in response to sustained receptor blockade, and compensatory increases in gastrin secretion that partially overcome the blockade.

The practical consequence is that H2 blockers are not reliably effective as the primary management tool for chronic, daily GERD in the way that PPIs are. A patient who starts famotidine for daily heartburn may have good symptom control in the first two weeks and find the effect substantially reduced by week six — not because their disease has worsened, but because the drug’s effectiveness has diminished through this receptor adaptation.

This does not mean H2 blockers are ineffective for daily use — it means they are most effective when used intermittently or on-demand rather than on a fixed daily schedule. The classic use cases where tachyphylaxis is not a problem include: taking famotidine 30 minutes before a meal known to trigger heartburn, taking it before bedtime on evenings when a large or late meal was consumed, or using it for a short course of 2 to 4 weeks when symptoms are temporarily more active. For patients who need daily acid suppression reliably maintained for months, a PPI is the more appropriate pharmacological choice.

H2 Blockers as Add-On Therapy With PPIs

One counterintuitive use of H2 blockers is as a supplementary agent alongside a PPI in patients with documented nocturnal acid breakthrough. Some patients on once-daily PPIs experience overnight acid surges — a phenomenon where gastric pH falls to acidic levels during the night, causing nocturnal symptoms or damaging the esophageal lining. This occurs because parietal cells recover from daytime PPI inhibition overnight as new proton pumps are synthesised, and without a meal stimulus to activate the PPI taken in the morning, overnight acid production is relatively uninhibited.

Adding an H2 blocker (famotidine 20 mg) at bedtime has been shown to reduce nocturnal acid breakthrough in PPI-treated patients. The H2 blocker acts through a different receptor pathway than PPIs and is not subject to the same requirement for activated acid secretion for its own efficacy, making it effective during the overnight fasting period. This combination approach is used in specific clinical contexts — particularly in patients with erosive esophagitis not fully controlled on once-daily PPI, or in patients where nocturnal reflux is a documented symptom — rather than as routine add-on therapy.

The risk of developing H2 blocker tachyphylaxis is an argument for using this approach intermittently rather than nightly. Some gastroenterologists recommend nightly H2 blocker use for 4 to 6 weeks to address a period of active nocturnal symptoms, then reassessing whether the PPI dose should be increased rather than continuing both agents indefinitely.

Drug Interactions and Safety Profile

Famotidine’s safety profile is excellent for the majority of adults, with few meaningful drug interactions. The CYP450 interaction concerns that applied to cimetidine do not apply to famotidine. The main relevant interactions with famotidine are:

• Antacids: Taking an antacid within one hour of famotidine reduces its absorption. Allow at least one hour between doses when using both.
• Atazanavir and HIV medications: Like all acid-suppressing agents, H2 blockers raise gastric pH enough to reduce the absorption of pH-dependent HIV medications. Specific dosing timing guidance from the prescribing HIV specialist should be followed.
• Dasatinib: This leukaemia medication requires an acidic stomach environment for dissolution; H2 blockers and PPIs are specifically contraindicated with it.

Beyond drug interactions, famotidine’s known side-effect profile at OTC doses (10–20 mg) is minimal — headache and dizziness are the most reported adverse effects and are uncommon. At prescription doses used for erosive esophagitis (40 mg twice daily), the safety profile remains favourable. There is no equivalent of the long-term nutritional deficiency concern with famotidine that exists with PPIs — H2 blockers at standard doses do not produce sufficient acid suppression to impair B12 cleavage from food or significantly affect mineral absorption.

The NHS famotidine information page provides a practical prescribing summary accessible to patients and caregivers. For a comparison of the full interaction profiles across all acid management classes, the MedlinePlus drug information database offers a searchable resource.

H2 Blockers in Pregnancy and Breastfeeding

Famotidine is considered one of the safer acid management options in pregnancy. While the evidence base for famotidine in pregnancy is less extensive than for ranitidine (which was widely used before its withdrawal), available data have not identified significant teratogenic risk at standard OTC doses. Most prescribing guidelines recommend calcium carbonate antacids as the first-line intervention for gestational heartburn, with famotidine as a second-line option when antacids are insufficient. PPIs are typically reserved for severe or erosive reflux in pregnancy. Any pharmacological treatment of heartburn in pregnancy should be discussed with the overseeing midwife or obstetrician.

Famotidine is excreted in breast milk. The amount transferred to an exclusively breastfed infant at standard maternal doses is generally considered too small to produce clinically significant effects, but medical guidance should still be sought for breastfeeding mothers requiring regular use.

H2 Blockers in Older Adults

Famotidine is generally well tolerated in older adults and does not carry the CYP interaction risks of cimetidine. However, several points apply to older adults specifically. Reduced renal clearance in older adults means famotidine is eliminated more slowly — dose reduction is recommended in patients with estimated GFR below 50 mL/min/1.73m². Signs of over-sedation from accumulating famotidine include confusion, dizziness, and headache, which may be missed if attributed to other conditions. The prescribing guidance from the FDA and product monographs specifically address renal dose adjustment for famotidine in this context.

Cimetidine should generally be avoided in older adults on multiple medications due to its extensive CYP450 interactions — a concern that applies with even greater force when the patient’s medication list includes anticoagulants, antiepileptics, or antiarrhythmics. For older adults managing acid reflux who need something stronger than an antacid, famotidine is the appropriate H2 blocker choice. The lifestyle measures that reduce acid reflux burden — covered in the article on healthy habits for liver and digestive health — are often highly effective in reducing the frequency and dose of H2 blocker use needed in older adults.

Comparing Acid Management Options: A Practical Framework

Choosing between an antacid, an H2 blocker, and a PPI is most straightforward when you match the drug class to the symptom pattern and context. The following framework applies to most adults with uncomplicated heartburn or acid reflux:

Antacid (calcium carbonate, magnesium hydroxide, alginate): Choose when symptoms are occasional (fewer than twice per week), unpredictable, and already present. Antacids work within 5 to 10 minutes and provide 20 to 60 minutes of relief. They are the right tool for a sudden after-meal heartburn episode and for rescue relief when other medications have not fully covered symptoms. They are not appropriate as the primary management for predictable or frequent reflux.

H2 blocker (famotidine): Choose when symptoms are predictable and situational, or when you want to prevent heartburn from a known trigger rather than treat it after the fact. Take famotidine 30 to 60 minutes before the trigger meal or before lying down. H2 blockers are also appropriate for patients stepping down from PPIs, for supplementing PPIs with nocturnal cover, or for patients on clopidogrel who need acid suppression without a significant CYP interaction. They are not appropriate as the primary daily medication for chronic GERD with mucosal damage, due to tachyphylaxis.

Proton pump inhibitor (omeprazole, lansoprazole, etc.): Choose when symptoms occur daily or near-daily, when there is confirmed esophageal mucosal damage (erosive esophagitis), when healing of a peptic ulcer or eradication of H. pylori is the goal, or when NSAID gastroprotection is required. PPIs are more effective than H2 blockers in these scenarios and do not develop tachyphylaxis with continuous use. Their long-term risks are manageable with appropriate monitoring and periodic reassessment. Take PPIs 30 to 60 minutes before the first meal of the day for optimal activation.

If your symptoms don’t clearly fit one category — for instance, if you have daily symptoms but no confirmed mucosal damage and are reluctant to start a PPI — a 2-week trial of a twice-daily H2 blocker as a diagnostic step is reasonable. If symptoms resolve, an H2 blocker on-demand may suffice. If they recur as soon as the H2 blocker is stopped, or if the H2 blocker provides diminishing relief after two weeks, a formal GP review to assess whether a PPI trial is warranted is the appropriate next step.

Frequently Asked Questions